Literature DB >> 28958619

From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor.

Nicholas Kindon1, Andrew Davis2, Iain Dougall2, John Dixon2, Timothy Johnson2, Iain Walters2, Steve Thom2, Kenneth McKechnie2, Premji Meghani2, Michael J Stocks3.   

Abstract

The G protein-coupled P2Y2 receptor, activated by ATP and UTP has been reported as a potential drug target for a wide range of important clinical conditions, such as tumor metastasis, kidney disorders, and in the treatment of inflammatory conditions. However, pharmacological studies on this receptor have been impeded by the limited reported availability of stable, potent and selective P2Y2R antagonists. This article describes the design and synthesis of AR-C118925, a potent and selective non-nucleotide antagonist of the P2Y2 receptor discovered using the endogenous P2Y2R agonist UTP as the chemical starting point.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AR-C118925; Antagonist; P2; P2Y(2); Purinergic

Mesh:

Substances:

Year:  2017        PMID: 28958619     DOI: 10.1016/j.bmcl.2017.09.043

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Characterisation of P2Y2 receptors in human vascular endothelial cells using AR-C118925XX, a competitive and selective P2Y2 antagonist.

Authors:  Markie O Muoboghare; Robert M Drummond; Charles Kennedy
Journal:  Br J Pharmacol       Date:  2019-07-06       Impact factor: 8.739

2.  Profiling of a suramin-derived compound library at recombinant human P2Y receptors identifies NF272 as a competitive but non-selective P2Y2 receptor antagonist.

Authors:  Nicole Brockmann; Parichat Sureechatchaiyan; David Müller; Tatiana Hennicke; Ralf Hausmann; Gerhard Fritz; Alexandra Hamacher; Matthias U Kassack
Journal:  Purinergic Signal       Date:  2019-07-03       Impact factor: 3.765

3.  Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmonary artery using selective antagonists.

Authors:  Markie O Dales; Callum Mitchell; Alison M Gurney; Robert M Drummond; Charles Kennedy
Journal:  Purinergic Signal       Date:  2022-08-26       Impact factor: 3.950

Review 4.  Therapeutic potential for P2Y2 receptor antagonism.

Authors:  Kimberly J Jasmer; Kevin Muñoz Forti; Lucas T Woods; Seunghee Cha; Gary A Weisman
Journal:  Purinergic Signal       Date:  2022-10-11       Impact factor: 3.950

5.  Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.

Authors:  Sean Conroy; Nicholas D Kindon; Jacqueline Glenn; Leigh A Stoddart; Richard J Lewis; Stephen J Hill; Barrie Kellam; Michael J Stocks
Journal:  J Med Chem       Date:  2018-03-28       Impact factor: 7.446

Review 6.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

7.  P2Y2 Receptors Mediate Masseter Muscle Mechanical Hypersensitivity in Rats.

Authors:  Petra Tariba Knežević; Robert Vukman; Mia Uhač; Davor Illeš; Daniela Kovačević Pavičić; Sunčana Simonić-Kocijan
Journal:  J Pain Res       Date:  2020-06-03       Impact factor: 3.133

Review 8.  Recommended tool compounds and drugs for blocking P2X and P2Y receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Purinergic Signal       Date:  2021-09-02       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.